Home / API Products / Formoterol Fumarate Dihydrate
Formoterol Fumarate Dihydrate
General information about the Formoterol Fumarate Dihydrate active pharmaceutical ingredient
Formoterol Fumarate Dihydrate as active pharmaceutical ingredient (API) is a beta2-agonist used in the management of COPD and asthma. Formoterol Fumarate Dihydrate works on bronchial smooth muscle to dilate and relax airways. Formoterol Fumarate Dihaydrate is found in combination with budesonide, mometasone and aclidinium bromide. Formoterol Fumarate Dihaydrate is mainly found as aerosol and solution.
Therapeutic area
Respiratory
Monograph
- PH.EUR.
- USP
Available grade
Micronized
Regulatory documentation
- CEP
- US DMF**
Produced in
GRO
Product Category
High Potent Substances
Axplora manufactures Formoterol Fumarate Dihydrate API
Formoterol Fumarate Dihydrate API is manufactured in cGMP by Axplora via chemical synthesis from early stage starting material. Formoterol Fumarate Dihydrate API is produced by Farmabios, our EUGMP, USFDA and PMDA approved manufacturing site with legal seat in Gropello Cairoli, Italy. Farmabios’ expertise is to make and handle with steroids, niche hormones, and highly potent active pharmaceutical ingredient (HPAPI), including cytotoxic drugs. Formoterol Fumarate Dihydrate API is commercially available in multiple micronized grades specifically designed around various formulation requirements. Formoterol Fumarate Dihydrate API customized particle size distribution (PSD) grades, including post milling conditioning, and tailor-made packaging solutions are available upon request. Feel free to contact us if you need any additional information about Formoterol Fumarate Dihydrate API.
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.